LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial

• DOI: 10.1016/j.annonc.2022.08.007
• Publication Date: 2022-09-13T22:33:29Z
• Authors: I. Nederlof; O.I. Isaeva; N. Bakker; M. de Graaf; R.F. Salgado; N. Klioueva; K. Van De Vijver; F. van Duijnhoven; E. Kalashnikova; S. Willingham; S. Luykx; C.E. Loo; E. Kerver; G.S. Sonke; C.U. Blank; R. Mann; S.C. Linn; D. Lambrechts; H. Horlings; M. Kok
• Keywords: Tumor-infiltrating lymphocytes; Triple-negative breast cancer